Immunomodulator and calcineurin inhibitors on inflammatory bowel disease.
Miki MiuraMari HayashidaTadakazu HisamatsuPublished in: Nihon rinsho. Japanese journal of clinical medicine (2019)
Immunomodulator (thiopurines) and calcineurin inhibitors (cyclosporine, tacrolimus) have been used in IBD treatment. Thiopurines such as azathioprine and 6-mercaptopur- ine are used in steroid refractory and steroid dependent UC patients. They are also concomitant used both in CD and UC with other drugs including anti-TNFa monoclonal Ab mainly as maintenance therapy. Calcineurin inhibitors, cyclosporine and tacrolimus, are used in moderate to severe refractory UC patients. Adverse effects of thiopruine include bone marrow suppression, liver dysfunction, hair loss, and infectious disease. Recently, it was reported that the risk of acute onset leukopenia in thioprine use is associated with NUDT 15 gene variant, especially in Asian population. Renal dysfunction and infectious disease (e. g. pneumocystis) should be concerned in the patientg treated with calcineurin inhibitors.
Keyphrases
- end stage renal disease
- infectious diseases
- bone marrow
- chronic kidney disease
- newly diagnosed
- ejection fraction
- peritoneal dialysis
- mesenchymal stem cells
- oxidative stress
- prognostic factors
- gene expression
- drug induced
- high intensity
- copy number
- cell therapy
- multiple myeloma
- nk cells
- respiratory failure
- extracorporeal membrane oxygenation
- mechanical ventilation
- transcription factor
- genome wide identification